ClinicalTrials.gg
CompletedNCT07394452Updated Feb 6, 2026

Single Ascending Dose Study(SAD),Multiple Ascending Dose Study(MAD) , High-fat Diet Study (FE) of TJ0113 Capsules in Healthy Subjects

A Phase 1 interventional study of TJ0113 Capsules and Placebo in Healthy Subjects, sponsored by Hangzhou PhecdaMed Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Hangzhou PhecdaMed Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Aug 2023, registered Jan 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study included three clinical studies, namely a single ascending dose (SAD) study, a multiple ascending dose (MAD) study, and a high-fat diet food effect (FE) study.

Read the detailed description

Study 1: SAD study A single-center, randomized, double-blind, placebo-controlled, single ascending dose study of TJ0113 capsules in healthy subjects. Six dose groups (A1-A6) were established, with doses of 80 mg, 160 mg, 260 mg, 400 mg, 540 mg, and 720 mg, respectively.

A total of 72 healthy adult subjects (12 per group) were enrolled, including both males and females. Subjects in each dose group were randomized in a 5:1 ratio to receive either the investigational product, TJ0113 capsules, or placebo (10 subjects received the investigational product and 2 subjects received placebo). Two subjects in the 80 mg dose group were set as a sentinel arm and were randomized in a 1:1 ratio to receive either TJ0113 capsules or placebo. After completing the 24-hour safety observation following sentinel dosing, the remaining 10 subjects in the 80 mg dose group were randomized in a 9:1 ratio to receive either TJ0113 capsules or placebo.

Study 2: MAD study In the single-center, randomized, double-blind, placebo-controlled, MAD study of TJ0113 capsules in healthy subjects, 3 dose groups (B1 to B3) of 200 mg once daily(QD), 400 mg QD, 300 mg twice daily(BID )were set.

A total of 36 healthy adult subjects (12 per group) were enrolled, including both males and females. Subjects in each dose group were randomized in a 5:1 ratio to receive either the investigational product, TJ0113 capsules, or placebo (10 subjects received the investigational product and 2 subjects received placebo). Subjects in the 200 mg and 400 mg dose groups received once-daily (QD) dosing, while subjects in the 300 mg BID dose group received twice-daily (BID) dosing administered with warm water, for 7 consecutive days (only one dose in the morning on Day 7).

Study 3: FE study A single-center, single-dose, randomized, open-label, 2-sequence, 2-period, crossover study to evaluate the effect of a standard high-fat diet on the pharmacokinetics of TJ0113 capsules after single oral administration (200 mg) in healthy subjects.

A total of 20 healthy adult subjects were enrolled in this period and randomized in a 1:1 ratio to 2 dosing sequences (C1: fasting-fed; C2: fed-fasting), with 10 subjects per group (all receiving the investigational product TJ0113 capsule). Each dosing sequence consisted of 2 cycles with 1 dose administered in each cycle. Group C1 received the dose in a fasting state during the first cycle and in a fed state during the second cycle; Group C2 received the dose in a fed state during the first cycle and in a fasting state during the second cycle . The two cycles were separated by a 7-day washout period.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Hangzhou PhecdaMed Co., Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the clinical trial, sign the form, understand and agree to follow the protocol, have a full understanding of trial contents, process, and possible adverse reactions, and indicate the date of signing;
  2. Aged 18 \~ 55 years (inclusive), Chinese healthy male or female;
  3. Body weight ≥ 50 kg (male) or ≥ 45 kg (female), (BMI) within the range of 19.0 \~ 26.0 kg/m2 (inclusive);
  4. Subjects and their partners have no plans for pregnancy, donation of sperm or eggs, and voluntarily take effective measures (such as abstinence, condom, etc.) from the screening phase until 6 months after the end of the trial;
  5. Able to communicate well with the investigator, understand and agree to follow all requirements of this trial.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history or current presence of chronic diseases involving the cardiovascular, respiratory, urinary, nervous, psychiatric, hematological, endocrine and metabolic (diabetes, thyroid disease, adrenal disease), and immune systems, and deemed unsuitable for participation by the investigator.
  2. Subjects who have received surgery within 3 months before screening, or plan to receive surgery during the trial; or have received medical or surgical treatment (such as gastrointestinal surgery) permanently changing the absorption, distribution, metabolism and excretion of oral drugs (except for hernia repair); a history of abdominal surgery, such as cholecystectomy (except for uncomplicated appendectomy and endoscopic treatment of gastrointestinal polyps after 6 months);
  3. Subjects with dysphagia or gastrointestinal, liver, or kidney diseases (regardless of whether they have been cured) within 6 months before screening that could affect drug absorption or excretion;
  4. History of drug allergy or specific allergic diseases (such as asthma, urticaria) or known to the product or its ;
  5. Subjects who have used any drugs (including prescription drugs, over-the-counter drugs, Chinese herbal medicines, etc.) or supplements within 14 days before the first dose;
  6. Subjects with abnormal and clinically significant results on physical examination, vital signs, laboratory tests (blood routine test, urinalysis + specific gravity, blood biochemistry, coagulation function, etc.) at screening and baseline;
  7. Subjects with clinically significant 12-lead abnormalities at screening or baseline, or with an average (corrected QT interval using Fridericia's formula) >450 ms for males, >470 ms for females, QRS >120 ms, or a history of long QT syndrome.
  8. Subjects who have special dietary requirements and cannot abide by the standard diet;
  9. Subjects who are difficult to collect blood samples or cannot tolerate venipuncture, and have a history of fainting at the sight of blood or needles;
  10. Subjects who have blood donation or non-physiological blood loss ≥ 400 mL (including trauma, blood collection, blood donation, etc., except for physiological blood loss in females) within 3 months before screening, or blood transfusion; or blood donation or non-physiological blood loss ≥ 200 mL within 1 month before screening; or blood donation or blood components planned during the study or within 3 months after the end of the study;
  11. Subjects who have excessively used nicotine products (more than 5 cigarettes in average daily) within 3 months before screening and cannot stop using any tobacco products throughout the trial; subjects with positive urine cotinine tests;
  12. Subjects who have consumed more than 14 units of alcohol per week within 6 months prior to screening (1 unit of alcohol ≈ 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine), have a positive alcohol breath test at baseline (breath alcohol content >0.0 mg/100 mL), or cannot abstain from alcohol during the trial;
  13. Subjects who have long-term excessive consumption of tea, coffee, or caffeinated beverages (more than 8 cups per day, 1 cup = 200 mL) within the year prior to screening; subjects who have consumed any foods or beverages containing caffeine, alcohol, xanthine, or grapefruit components, or other substances that affect drug absorption, distribution, metabolism, and excretion (such as coffee, tea, chocolate, etc.) within 48 hours before the first dose;
  14. Subjects who have received inoculations within 14 days before screening or plan to receive them during the trial or within 1 month after dosing, including but not limited to measles, mumps, rubella, varicella, yellow fever, rabies, Bacillus Calmette-Guerin Vaccine (BCG), typhoid vaccine, COVID-19 vaccine, etc.;
  15. Subjects who have febrile illness or active infection within 14 days before screening;
  16. Subjects who have used any known hepatic enzyme inducers or inhibitors within 30 days before the first dose;
  17. Subjects with drug addiction or positive drug abuse tests, or a history of drug abuse/dependence or drug use within 1 year before screening;
  18. Subjects with positive results on infectious disease screening, including positive (HIV) antigen/antibody, positive surface antigen (HBsAg) quantification, positive virus (HCV) antibody, positive Treponema pallidum antibody tests;
  19. Subjects with positive pregnancy tests at screening or baseline, who are pregnant, breastfeeding, or planning to become pregnant during the trial, or men or women of who are unwilling to use effective for 6 months after the last dose;
  20. Subjects who are unable to comply with all requirements of the study or still need to engage in or plan to participate in strenuous physical activity or exercise during the trial, including body contact or collision sports;
  21. Subjects who have participated in other clinical trials of drugs or medical devices within 3 months before screening, and received investigational products or medical devices; or planned to participate in other trials during the study period; or within 5 half-lives of another drug before screening (if 5 half-lives exceed 3 months);
  22. Employees or related personnel of the investigator, study site, sponsor, or contract research organization (CRO).Subjects who have other conditions that could impact compliance in the opinion of the investigator or who are unable to participate in the trial due to personal reasons.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose (SAD): 80 mg

    Participants will receive single oral administration of 80 mg TJ0113.

    Drug: TJ0113 Capsules

  • Experimental
    Single Ascending Dose (SAD): 160 mg

    Participants will receive single oral administration of 160 mg TJ0113.

    Drug: TJ0113 Capsules

  • Experimental
    Single Ascending Dose (SAD): 260 mg

    Participants will receive single oral administration of 260 mg TJ0113.

    Drug: TJ0113 Capsules

  • Experimental
    Single Ascending Dose (SAD): 400 mg

    Participants will receive single oral administration of 400 mg TJ0113.

    Drug: TJ0113 Capsules

  • Experimental
    Single Ascending Dose (SAD): 540 mg

    Participants will receive single oral administration of 540 mg TJ0113.

    Drug: TJ0113 Capsules

  • Experimental
    Single Ascending Dose (SAD): 720 mg

    Participants will receive single oral administration of 720 mg TJ0113.

    Drug: TJ0113 Capsules

  • Placebo comparator
    Single Ascending Dose (SAD): placebo

    Participants will receive single oral administration of Placebo.

    Other: Placebo

  • Experimental
    Multiple Ascending Dose (MAD): 200 mg QD

    Participants will receive oral administration of 200 mg TJ0113 once daily for 7 days

    Drug: TJ0113 Capsules

  • Experimental
    Multiple Ascending Dose (MAD): 400 mg QD

    Participants will receive oral administration of 400 mg TJ0113 once daily for 7 days

    Drug: TJ0113 Capsules

  • Experimental
    Multiple Ascending Dose (MAD): 300 mg BID

    Participants will receive oral administration of 300 mg TJ0113 twice daily for 7 days

    Drug: TJ0113 Capsules

  • Placebo comparator
    Multiple Ascending Dose (MAD): placebo

    Participants will receive oral administration of placebo for 7 days

    Other: Placebo

  • Experimental
    Food Effect: 200 mg C1: fasting-fed

    Group C1 received oral administration of 200 mg TJ0113 once in a fasting state during the first cycle and received oral administration of 200 mg TJ0113 once in a fed state during the second cycle. The two cycles were separated by a 7-day washout period.

    Drug: TJ0113 Capsules

  • Experimental
    Food Effect: 200 mg C2: fed-fasting

    Group C2 received oral administration of 200 mg TJ0113 once in a fed state during the first cycle and received oral administration of 200 mg TJ0113 once in a fasting state during the second cycle. The two cycles were separated by a 7-day washout period.

    Drug: TJ0113 Capsules

Interventions

  • Participants will receive oral administration of TJ0113.

  • OtherPlacebo

    Participants will receive oral administration of Placebo.

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse event (TEAE) incidence of TJ0113 capsules after single oral administration in SAD study

    Types, incidence rates, and severity of adverse events. Safety evaluation indicators include, but are not limited to, the following items: adverse events, physical examination, vital signs, electrocardiogram (ECG), laboratory test results (coagulation function, complete blood count, blood biochemistry, urinalysis plus urine specific gravity, etc.)

    Time frame: Within 12 days after the last administration

  2. Treatment-emergent adverse event (TEAE) incidence of TJ0113 capsules after multiple oral administration in MAD study

    Types, incidence rates, and severity of adverse events. Safety evaluation indicators include, but are not limited to, the following items: adverse events, physical examination, vital signs, electrocardiogram (ECG), laboratory test results (coagulation function, complete blood count, blood biochemistry, urinalysis plus urine specific gravity, etc.)

    Time frame: Within 12 days after the last administration

Secondary outcomes

  1. Maximum concentration (Cmax) of TJ0113 capsules after oral administration in SAD study

    PK parameters for the SAD study mainly included maximum concentration (Cmax)

    Time frame: Within 72 hours after the last administration

  2. Area under the plasma concentration versus time curve (AUC) of TJ0113 capsules after oral administration in SAD study

    PK parameters for the SAD study mainly included area under the plasma concentration versus time curve (AUC)

    Time frame: Within 72 hours after the last administration

  3. Half life(t1/2) of TJ0113 capsules after oral administration in SAD study

    PK parameters for the food effect study mainly included half life(t1/2)

    Time frame: Within 72 hours after the last administration

  4. Time to maximum concentration (Tmax) of TJ0113 capsules after oral administration in SAD study

    PK parameters for the food effect study mainly included time to maximum

    Time frame: Within 72 hours after the last administration

  5. Maximum concentration (Cmax) of TJ0113 capsules after oral administration in MAD study

    PK parameters for the MAD study mainly included maximum concentration (Cmax)

    Time frame: Within 72 hours after the last administration

  6. Area under the plasma concentration versus time curve (AUC) of TJ0113 capsules after oral administration in MAD study

    PK parameters for the MAD study mainly included area under the plasma concentration versus time curve (AUC)

    Time frame: Within 72 hours after the last administration

  7. Half life(t1/2) of TJ0113 capsules after oral administration in MAD study

    PK parameters for the food effect study mainly included half life(t1/2)

    Time frame: Within 72 hours after the last administration

  8. Time to maximum concentration (Tmax) of TJ0113 capsules after oral administration in MAD study

    PK parameters for the food effect study mainly included time to maximum

    Time frame: Within 72 hours after the last administration

  9. Maximum concentration (Cmax) of TJ0113 capsules after oral administration with a standard high-fat diet in FE

    PK parameters for the FE study mainly included maximum concentration (Cmax)

    Time frame: Within 72 hours after the last administration

  10. Area under the plasma concentration versus time curve (AUC) of TJ0113 capsules after oral administration with a standard high-fat diet in FE study

    PK parameters for the FE study mainly included area under the plasma concentration versus time curve (AUC)

    Time frame: Within 72 hours after the last administration

  11. Half life(t1/2) of TJ0113 capsules after oral administration with a standard high-fat diet in FE study

    PK parameters for the food effect study mainly included half life(t1/2)

    Time frame: Within 72 hours after the last administration

  12. Time to maximum concentration (Tmax) of TJ0113 capsules after oral administration with a standard high-fat diet in FE study

    PK parameters for the food effect study mainly included time to maximum

    Time frame: Within 72 hours after the last administration

  13. Treatment-emergent adverse event (TEAE) incidence of TJ0113 capsules after multiple oral administration with a standard high-fat diet in FE study

    Types, incidence rates, and severity of adverse events. Safety evaluation indicators include, but are not limited to, the following items: adverse events, physical examination, vital signs, electrocardiogram (ECG), laboratory test results (coagulation function, complete blood count, blood biochemistry, urinalysis plus urine specific gravity, etc.)

    Time frame: Within 15 days after the last administration

07

Study locations

1 site
  • Zhejiang Xiaoshan hospital
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Feb 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 6, 2026
StartActual
Aug 4, 2023
Primary completionActual
Feb 5, 2024
CompletionActual
Apr 3, 2024
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07394452
Lead sponsor
Hangzhou PhecdaMed Co., Ltd.
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Aug 4, 2023
Primary completion
Feb 5, 2024
Completion
Apr 3, 2024
Last update
Feb 6, 2026

Study contacts

Jian Chen
principal investigator · Zhejiang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TJ0113

Start the discussion